Highlights Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Delayed Nasdaq Other stock markets 14:11:53 2024-05-10 EDT			5-day change	1st Jan Change
0.66 ^USD	+0.15%		-9.92%	-42.79%

05-07	Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week	CI
04-25	Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week	05-07	CI
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	04-25	CI
Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	04-09	CI
Mainz Biomed N.V. Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic	03-05	CI
Mainz Biomed Announces Distribution Partnership with Praxisdienst for Coloalert®	02-22	CI
Mainz Biomed N.V. Establishes Strategic Partnership with Tomalab to Expand Availability of Coloalert in Italy	02-21	CI
Mainz Biomed Launches New Laboratory in Germany	02-06	MT
Mainz Biomed N.V. and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees	12-19	CI
Mainz Biomed N.V. Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers	12-05	CI
Mainz Biomed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Mainz Biomed Nv Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence to Develop Next-Generation Colorectal Screening Test	11-09	CI
Mainz Biomed N.V. Presents Results of Colofuture Study	23-10-18	CI
Mainz Biomed Launches Colorectal Cancer Detection Test in Romania	23-10-04	MT
Mainz Biomed, Bioclinica Introduce Colorectal Cancer Screening Test in Romania	23-10-04	MT
Mainz Biomed N.V. Announces Live Launch of Coloalert® with Bioclinica in Romania	23-10-04	CI
Mainz Biomed N.V. Announces Positive Topline Results from its ColoFuture Study	23-09-13	CI
Mainz Biomed Signs Strategic Partnership with German Laboratory	23-09-05	MT
Mainz Biomed Taps Arztliches Labor Dr. Buhlmann as Partner for ColoAlert in Germany	23-09-05	MT
Germany's Mainz Biomed Launches Colorectal Cancer Test Kit in in Poland	23-08-22	MT
Mainz Biomed Announces Live Launch of ColoAlert with testDNA Laboratory in Poland	23-08-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Highlights

Filters